These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31992357)

  • 1. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
    Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
    Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posterior fossa ependymoma: current insights.
    Thompson YY; Ramaswamy V; Diamandis P; Daniels C; Taylor MD
    Childs Nerv Syst; 2015 Oct; 31(10):1699-706. PubMed ID: 26351223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
    Azizgolshani N; Petersen CL; Chen Y; Levy JJ; Salas LA; Perreard L; Nguyen LN; Christensen BC
    Clin Epigenetics; 2021 Sep; 13(1):176. PubMed ID: 34538273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated
    Ramsawhook A; Lewis L; Coyle B; Ruzov A
    Clin Epigenetics; 2017; 9():18. PubMed ID: 28228863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
    Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
    Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
    Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
    Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
    Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
    Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
    Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
    PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
    Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM
    Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
    Ahsan S; Raabe EH; Haffner MC; Vaghasia A; Warren KE; Quezado M; Ballester LY; Nazarian J; Eberhart CG; Rodriguez FJ
    Acta Neuropathol Commun; 2014 Jun; 2():59. PubMed ID: 24894482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
    Shu C; Wang Q; Yan X; Wang J
    Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.
    Amani V; Donson AM; Lummus SC; Prince EW; Griesinger AM; Witt DA; Hankinson TC; Handler MH; Dorris K; Vibhakar R; Foreman NK; Hoffman LM
    J Neuropathol Exp Neurol; 2017 Jul; 76(7):595-604. PubMed ID: 28863455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
    Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
    J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
    Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
    Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma.
    Zhao F; Zhang ZW; Zhang J; Zhang S; Zhang H; Zhao C; Chen Y; Luo L; Tong WM; Li C; Niu Y; Liu P
    Front Oncol; 2021; 11():603686. PubMed ID: 33718152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Deadly Silence of Posterior Fossa A Ependymoma.
    Lin GL; Monje M
    Mol Cell; 2020 Jun; 78(6):999-1001. PubMed ID: 32559429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.